Contineum Therapeutics, Class Stock Shares Owned By Insiders
| CTNM Stock | 10.65 0.36 3.27% |
Fundamental analysis of Contineum Therapeutics, allows traders to better anticipate movements in Contineum Therapeutics,'s stock price by examining its financial health and performance throughout various phases of its business cycle.
Contineum | Shares Owned By Insiders | Build AI portfolio with Contineum Stock |
Contineum Therapeutics, Class Company Shares Owned By Insiders Analysis
Contineum Therapeutics,'s Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Contineum Therapeutics, Shares Owned By Insiders | 1.60 % |
Most of Contineum Therapeutics,'s fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Contineum Therapeutics, Class is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Contineum Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for Contineum Therapeutics, is extremely important. It helps to project a fair market value of Contineum Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since Contineum Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Contineum Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Contineum Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 1.6% of Contineum Therapeutics, Class are shares owned by insiders. This is 89.46% lower than that of the Pharmaceuticals sector and 88.72% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 84.14% higher than that of the company.
Contineum Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Contineum Therapeutics,'s direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Contineum Therapeutics, could also be used in its relative valuation, which is a method of valuing Contineum Therapeutics, by comparing valuation metrics of similar companies.Contineum Therapeutics, is currently under evaluation in shares owned by insiders category among its peers.
Contineum Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Contineum Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Contineum Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Contineum Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 131.72 M | ||||
| Shares Outstanding | 21.63 M | ||||
| Shares Owned By Insiders | 1.60 % | ||||
| Shares Owned By Institutions | 74.09 % | ||||
| Number Of Shares Shorted | 1.15 M | ||||
| Price To Book | 1.76 X | ||||
| Price To Sales | 11.15 X | ||||
| EBITDA | (42 M) | ||||
| Net Income | (42.26 M) | ||||
| Total Debt | 6.26 M | ||||
| Book Value Per Share | 7.66 X | ||||
| Cash Flow From Operations | (32.84 M) | ||||
| Short Ratio | 6.44 X | ||||
| Earnings Per Share | (2.25) X | ||||
| Target Price | 22.75 | ||||
| Number Of Employees | 41 | ||||
| Market Capitalization | 321.3 M | ||||
| Total Asset | 212.85 M | ||||
| Retained Earnings | (117.4 M) | ||||
| Working Capital | 196.41 M | ||||
| Net Asset | 212.85 M |
About Contineum Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Contineum Therapeutics, Class's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Contineum Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Contineum Therapeutics, Class based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Contineum Therapeutics, Piotroski F Score and Contineum Therapeutics, Altman Z Score analysis. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Contineum Therapeutics,. If investors know Contineum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Contineum Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Contineum Therapeutics, is measured differently than its book value, which is the value of Contineum that is recorded on the company's balance sheet. Investors also form their own opinion of Contineum Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Contineum Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Contineum Therapeutics,'s market value can be influenced by many factors that don't directly affect Contineum Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Contineum Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Contineum Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Contineum Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.